PTC Therapeutics, Inc. (PTCT) Cash Flow Statement

The gap between net income and operating cash flow is the dominant signal here, as the ratio flips sign and magnitude repeatedly rather than settling into a stable relationship. Quarters such as 2025Q1, where net income of $866.6M was matched by operating cash flow of $870.1M, appear to reflect a one-time recognition event rather than recurring cash generation. Investors should monitor whether the next several quarters show operating cash flow tracking net income, as the current pattern warrants further investigation into earnings quality.

Excluding the 2025Q1 outlier, free cash flow has been negative in most reported quarters, which suggests the underlying operating base does not yet self-fund its cost structure. The swing in working capital, including a $110.7M inflow in 2026Q2 that reversed to a $110.7M outflow in 2026Q1, appears to be a larger driver of quarterly free cash flow than operations themselves. This pattern may indicate that reported free cash flow is timing-dependent and should not be extrapolated.

Such large reversals suggest collections timing, collaboration receivables, or payables settlement are the primary cash determinants rather than steady commercial activity. When working capital movements are of comparable size to the operating cash flow itself, the reported operating figure becomes less informative about recurring economics. Investors may wish to review receivables and deferred revenue balances to understand whether these reversals are timing differences or structural.

Stripping out the 2025Q1 event, the cumulative net result across the remaining quarters is negative, which suggests the business has not generated durable earnings or cash on a sustained basis. The reported equity-based compensation of roughly $17M to $24M per quarter is non-trivial relative to the operating cash flow generated in most periods. This analysis is based on reported figures and does not establish the cause of the divergence.